News
China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...
Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...
Roughly one in three preteens and teens ages 12 to 17 in the United States had prediabetes in 2023, according to new data ...
The first oral pill for obstructive sleep apnea (OSA) could be around the corner after pharmaceutical company Apnimed Inc.
Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.
(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...
Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...
Tirzepatide may confer larger increases in testosterone levels among men with metabolic hypogonadism than testosterone ...
In the third part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, outlines alternative reimbursement or value-based contracting models that could be feasible in the short term, ...
Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...
Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...
Teladoc Health is launching a new employee assistance program (EAP) called Wellbound, which it said is designed to promote a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results